Trial intelligence / Profile preview

Talabostat and Cisplatin in Advanced Melanoma

NCT00083252Phase 2Completed

Sponsor
Point Therapeutics
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of talabostat in melanoma, sponsored by Point Therapeutics. Status: completed.

02

Drugs

talabostat
03

Conditions

melanoma

Beyond the preview

Go deeper on NCT00083252.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00083252.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call